This study proposes a comprehensive framework for the joint optimization of maintenance actions and safety stock policies for multi-specification small-batch(MSSB)production.The production system considered consists o...This study proposes a comprehensive framework for the joint optimization of maintenance actions and safety stock policies for multi-specification small-batch(MSSB)production.The production system considered consists of multiple machines arranged in a series-parallel configuration.Given the multi-stage nature of the MSSB,a piecewise Gamma process is developed to model the degradation of machines owing to varying product specifications.A quality-based maintenance model is proposed to guide the scheduling of maintenance actions based on the observed product defect rate.The maintenance policy is optimized at two levels:at the machine level,the optimal quality of the produced products is determined,and at the system level,a threshold quality value is established to facilitate the opportunistic maintenance of machines.The relationship between the buffer stock and machine capacity is explicitly modeled to ensure production efficiency.A simulation-based multi-objective algorithm is employed to identify the optimal decision variable levels for the proposed maintenance policy.The numerical results demonstrate that the proposed method effectively balances the conflicting objectives of minimizing the expected operational costs and maximizing production efficiency.展开更多
Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research fie...Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.展开更多
基金supported by the Natural Science Foundation of Jiangsu Province(No.BK20210739)Natural Science Foundation of Colleges and Universities in Jiangsu Province(No.21KJB410002)+1 种基金Philosophy and Social Science Foundation of Colleges and Universities in Jiangsu Province(No.2021SJA2049)Humanities and Social Science Fund of Ministry of Education of China(No.24YJC630050).
文摘This study proposes a comprehensive framework for the joint optimization of maintenance actions and safety stock policies for multi-specification small-batch(MSSB)production.The production system considered consists of multiple machines arranged in a series-parallel configuration.Given the multi-stage nature of the MSSB,a piecewise Gamma process is developed to model the degradation of machines owing to varying product specifications.A quality-based maintenance model is proposed to guide the scheduling of maintenance actions based on the observed product defect rate.The maintenance policy is optimized at two levels:at the machine level,the optimal quality of the produced products is determined,and at the system level,a threshold quality value is established to facilitate the opportunistic maintenance of machines.The relationship between the buffer stock and machine capacity is explicitly modeled to ensure production efficiency.A simulation-based multi-objective algorithm is employed to identify the optimal decision variable levels for the proposed maintenance policy.The numerical results demonstrate that the proposed method effectively balances the conflicting objectives of minimizing the expected operational costs and maximizing production efficiency.
文摘Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.
